Login to Your Account

OxiGene 'Leader' In Approach Of Vascular Targeting For Cancer

By Randall Osborne

Monday, July 14, 2003

Gone are the days when a dollop of good news in any area of biotechnology lit a fire under stocks across the sector. Investors, having become at least somewhat more sophisticated, have narrowed their scrutiny to individual companies or platforms.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription